肾母细胞瘤组织中组织蛋白酶D、尿激酶型纤溶酶原激活剂及其受体的表达  

Expression of Cath D, uPA, and uPAR in nephroblastoma

作　　者：王家祥[1] 李守淼[1] 李琦[1] 范应中[1] 

机构地区：[1]郑州大学第一附属医院小儿外科,郑州450052

出　　处：《郑州大学学报（医学版）》2004年第2期217-219,共3页Journal of Zhengzhou University(Medical Sciences)

基　　金：河南省科技攻关基金资助项目 324410085

摘　　要：目的:探讨肾母细胞瘤组织中Cath D、uPA、uPAR的表达。方法:用免疫组化SABC法检测30例肾母细胞瘤及15例非肿瘤肾组织中Cath D、uPA、uPAR的表达。结果:肾母细胞瘤组织中Cath D、uPA、uPAR的阳性表达率分别为50％,53.3％和56.7％。而在非肿瘤肾组织中不表达,差异有统计学意义(P<0.05),3者的阳性表达率与组织学类型密切相关,FH型均低于UH型(P<0.05)..结论:Cath D、uPA、uPAR在肿瘤的浸润和转移中起重要作用,可作为预后的指标。Aim : To detect the expressions of Cath D, urokinase-type plasminogen activator ( uPA) and its receptor (uPAR) in nephroblastoma and reveal the correlation with histological type. Methods: The expressions of Cath D, uPA and uPAR as well as its correlationship with tumor histological type in 30 specimens of nephroblastoma and 15 non-tumor kidney tissues were retrospectively studied by using SABC immunohistochemistry. Results: The positive rates of expression of Cath D , upA , uPAR in nephroblastoma group were 50% , 53. 3% , 56. 7% respectively, but there were no positive staining in non-tumor kidney tissues. There were significant difference(P <0.05). The expressions of Cath D, uPA, uPAR were closely related to histological type. The expressions in FH were weaker than in UH ( P <0. 05). Conclusion; The findings suggest that Cath D, uPA and uPAR play an important role in invasion and metastasis of nephroblastoma. Cath D, uPA and uPAR might be independent predictors of prognosis.

关 键 词：织蛋白酶D 尿激酶型纤溶酶原激活剂 尿激酶型纤溶酶原激活剂受体 肾母细胞瘤 免疫组化 组织学类型 预后 

分 类 号：R737.11[医药卫生—肿瘤]